NCT05911035COMPLETEDN/ABackground: Mucormycosis is a life-threatening opportunistic fungal infection. Despite mucormycosis having existed for decades, it has gained notice of its widespread in many parts of the world during the second wave of the coronavirus disease 2019 (COVID-19) pandemic. The study aimed to determine the in-hospital outcomes of post-COVID-19 mucormycosis during the intensive care unit (ICU) stay in Egypt. Methods: This prospective cohort study included all patients admitted to the Medical ICU of the University Hospital who developed Mucormycosis with a history of previous COVID-19 infection. Clearance of previous COVID-19 was confirmed using PCR and high-resolution computed tomography (CT) on the chest before admission.
Inclusion Criteria: * confirmed previous COVID-19 infection with new mucormycosis infection Exclusion Criteria: * other fungal infections post-COVID-19 or mucormycosis infections without previous COVID-19
No linked publications found in PubMed